Active Complement Component 5 (C5)

Catalog#:PEH12792

概述（Summary）

别称（Alternative Names）	CPAMD4; C5a anaphylatoxin; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
纯度（Purity）	Greater than 95% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Ser1055-Asn1513】
Accession #	P01031
表达宿主（Host）	E.coli
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	55.2 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.; Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes.

C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

电泳图（SDS-PAGE image）



Greater than 95% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）



Figure 1. The binding activity of recombinant human C5 and recombinant mouse F2

Complement Component 5 (C5), which forms part of the later stages of the complement pathway, is cleaved into C5a and C5b. C5a is a chemotactic agent for neutrophils, while C5b forms part of the complement membrane attack complex. Coagulation Factor II (F2) has been identified as an interactor of C5, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human C5 and recombinant mouse F2. Briefly, C5 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to F2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-C5 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human C5 and recombinant mouse F2 was shown in Figure 1, the EC50 for this effect is 0.22 ug/mL.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.